Catalog No.
RHA29601
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Monoclonal
Applications
IHC, WB
Recommended Dilution
| Application |
Dilution |
| IHC |
1:50-1:100, WB: 1:500-1:1000 |
Target
Cell growth-inhibiting gene 1 protein, LPIC, Tripeptidyl-peptidase 1, Tripeptidyl aminopeptidase, Lysosomal pepstatin-insensitive protease, TPP1, CLN2, TPP-I, TPP-1, Tripeptidyl-peptidase I
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
O14773
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 4 ℃ for frequent use. Store at -20 ℃ for twelve months from the date of receipt.
Clone ID
R1D28
Note
For research use only.
The expression of late infantile neuronal ceroid lipofuscinosis (CLN2) gene product in human brains., PMID:9865940
A lysosomal proteinase, the late infantile neuronal ceroid lipofuscinosis gene (CLN2) product, is essential for degradation of a hydrophobic protein, the subunit c of ATP synthase., PMID:10349869
Rapid immunologic diagnosis of classic late infantile neuronal ceroid lipofuscinosis., PMID:10762513
Tripeptidyl peptidase I, the late infantile neuronal ceroid lipofuscinosis gene product, initiates the lysosomal degradation of subunit c of ATP synthase., PMID:10965052
Tripeptidyl-peptidase I in neuronal ceroid lipofuscinoses and other lysosomal storage disorders., PMID:11589013
Overexpression in colorectal carcinoma of two lysosomal enzymes, CLN2 and CLN1, involved in neuronal ceroid lipofuscinosis., PMID:16518810
Two novel CLN5 mutations in a Portuguese patient with vLINCL: insights into molecular mechanisms of CLN5 deficiency., PMID:16814585
Atypical CLN2 with later onset and prolonged course: a neuropathologic study showing different sensitivity of neuronal subpopulations to TPP1 deficiency., PMID:18283468
Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA., PMID:18473686
Intrathecal tripeptidyl-peptidase 1 reduces lysosomal storage in a canine model of late infantile neuronal ceroid lipofuscinosis., PMID:21784683
Altered expression of TPP1 in fibroblast-like synovial cells might be involved in the pathogenesis of rheumatoid arthritis., PMID:21833529
Long-term expression and safety of administration of AAVrh.10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis., PMID:23131032
Telomerase enzymatic component hTERT shortens long telomeres in human cells., PMID:24721976
Nonclinical evaluation of CNS-administered TPP1 enzyme replacement in canine CLN2 neuronal ceroid lipofuscinosis., PMID:25257657
Telomere Dysfunction Induced Foci (TIF) Analysis., PMID:27500188
Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy., PMID:29217732
Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 study., PMID:30205177
Mechanisms Inspired Targeting Peptides., PMID:32185724
Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration., PMID:33202105
Identification of tumor-associated antigens of lung cancer: SEREX combined with bioinformatics analysis., PMID:33587914
The intrinsically disordered N-terminal region of mouse DNA polymerase alpha mediates its interaction with POT1a/b at telomeres., PMID:33711210
Autocrine GMCSF Signaling Contributes to Growth of HER2+ Breast Leptomeningeal Carcinomatosis., PMID:34247146
Combination of chemotherapy and immune checkpoint therapy by the immunoconjugates-based nanocomplexes synergistically improves therapeutic efficacy in SCLC., PMID:35612299
For research use only. Not for human or drug use.
